Meet the team: Part 3
7 July 2022
Admescope welcomes Dr Laszlo Szilagyi, the newest member of the Business Development team, who will support the EU and APAC activities with his broad pharma and CRO experience.Read more
Meet the team: Part 2
13 April 2022
As part of our ‘meet the team’ series, Admescope welcomes Leah Haydock, a new US-based member of the Business Development team. With over 15 years of experience in international business, sales and marketing at companies including Evans Medical, Smith & Nephew and Cynosure, Leah is excited to join the company and put her background in pharmacology to good use.Read more
MIST evaluation toolbox – what is in there? Part 4
25 February 2022
The overall aim of the safety metabolism studies is to better understand human metabolism. How is the drug cleared, what metabolites are formed, what is the relative exposure to these and can they be considered safety tested through adequate exposures in toxicology species. The 4th part of this blog series concerns the MIST analysis, i.e. the metabolite exposure comparison performed utilising samples from repeated dose studies in man and toxicology species.Read more
Welcome 2022!
12 January 2022
Dear all, What a joy it is to address the Admescope 2021 Annual Letter as the new CEO. While my personal reflection to the past year comes with the flavor of few months of experience, I dare to extend it to further back – it already feels like the journey together had been longer, in all great ways!Read more
MIST evaluation toolbox – what is in there? Part 3
7 October 2021
In the first part of this blog series, Dr Johanna Haglund introduced what are the first steps in the Metabolites in Safety Testing evaluation (MIST). The second part advised how to proceed after in vitro cross-species comparison between human and safety species. This third part is about in vivo human MetID.Read more
